


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ernst Peter RIEBER
Title: ANTIBODIES TO DENDRITIC CELLS AND HUMAN DENDRITIC CELL
POPULATIONS AND USES THEREOF
Appl. No.: 09/700,200
Filing Date: 01/23/2001
Examiner: Gerald R. Ewoldt
Art Unit: 1644

RECEIVED

SEP 10 2002

TECH CENTER 1600/2900



LETTER TO EXAMINER

Commissioner for Patents
Box NON-FEE AMENDMENT
Washington, D.C. 20231

Sir:

Please find attached a Substitute Declaration for the above referenced application. Please note that this document is being filed in order to correct the following errors in the original declaration. The inventors name was listed in the incorrect order. The name should read: **Ernst Peter RIEBER**. We also listed the wrong country for the foreign priority application. The country should read: **Europe**. A copy of the first page of the published PCT application WO 99/58678 is attached to support both of these corrections.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date

September 6, 2002

FOLEY & LARDNER

Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5404

Facsimile: (202) 672-5399

By

Stephen A. Bent

Stephen A. Bent

Attorney for Applicant

Registration No. 29,768

Reg. No. 34,485



DT Rec'd PCT/PTO 06 SEP 2002
Atty. Dkt. No. 028622-0103

PG
1652
#15

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ernst Peter RIEBER
Title: ANTIBODIES TO DENDRITIC CELLS AND HUMAN DENDRITIC CELL
POPULATIONS AND USES THEREOF
Appl. No.: 09/700,200
Filing Date: 01/23/2001
Examiner: Gerald R. Ewoldt
Art Unit: 1644

RECEIVED
SEP 18 2002
TECH CENTER 1600/2900

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
Washington, D.C. 20231

Attn: Office of Initial Patent Examination, Customer Service Center

Sir:

Attached is a copy of the official Filing Receipt received from the PTO in the above-referenced application.

There is an error with respect to the inventors' name. The name should read:

Ernst Peter RIEBER.

There also is an error with respect to the country for the foreign priority application listed. The foreign application should read:

Europe 98 10 8534.3 05/11/1998.

The corrections are due to any error by Applicant and, we are submitting a Substitute Declaration and Power of Attorney to the Examiner concurrently herewith, any fees should be charge to Deposit Account No. 19-0741. Issuance of a corrected Filing Receipt is respectfully requested.

Respectfully submitted,

Date September 6, 2002

By Jayne A. Huleatt

FOLEY & LARDNER
Customer Number: 22428

Jayne A. Huleatt
Attorney for Applicant
Registration No. 34,485



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5542
Facsimile: (202) 672-5399



UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
SEP 18 2002

TECH CENTER

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/700,200	01/23/2001	1644	783	028622/0103	26	49	2

Stephen A Bent
Foley & Lardner
Washington Harbour
3000 K Street NW Suite 500
Washington, DC 20007-5109

FILING RECEIPT



OC000000005738914

Date Mailed: 02/09/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Peter Ernst Rieber, Olching, GERMANY;
Ernst Peter

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A 371 OF PCT/EP99/03218 05/11/1999

Foreign Applications

GERMANY 98 10 8534.3 05/11/1998
EUROPE

If Required, Foreign Filing License Granted 02/06/2001

** SMALL ENTITY **

Title

Antibodies to dendritic cells and human dendritic cell populations and uses thereof

Preliminary Class

530

Data entry by : ORDENEZ, MARTA

Team : OIPE

Date: 02/09/2001



LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED


No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231



NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

RECEIVED
SEP 11 2002
TECH CENTER 1600/2900

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY